# Dyslipidaemia Management > Dyslipidaemia management for FMGE Medicine: statin intensity by risk, LDL targets, triglyceride pancreatitis threshold and Indian NCD screening anchors. - Canonical URL: https://prepelephant.com/topics/fmge/medicine/dyslipidaemia-management - Exam / course: FMGE · Subject: Medicine - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-02 - Last updated: 2026-10-02 - How to cite: "Dyslipidaemia Management", PrepElephant, https://prepelephant.com/topics/fmge/medicine/dyslipidaemia-management ## Direct answer Statin intensity is matched to cardiovascular risk, not to a single cholesterol number: established atherosclerotic disease or diabetes with risk factors earns a high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) with low-density lipoprotein commonly targeted below 70 mg/dL, while most primary-prevention patients do well on moderate intensity (atorvastatin 10-20 mg). Fibrates are added only when triglycerides exceed about 500 mg/dL to prevent pancreatitis, and statin-myopathy questions resolve on creatine kinase. Indian patients develop coronary disease a decade earlier and at lower body mass than Western cohorts — the NPCDCS (now subsumed into the NP-NCD framework) screens adults from 30 years. Lifestyle remains the base of every prescription: diet, tobacco cessation, exercise, and control of blood pressure and glucose. ## What you must remember - **Statin ladder:** moderate intensity — atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg (LDL fall 30-49 percent); high intensity — atorvastatin 40-80 mg, rosuvastatin 20-40 mg (LDL fall 50 percent or more). - **Target logic:** very-high-risk (recurrent events, multivessel disease) is commonly targeted below 55 mg/dL; high-risk below 70; lower-risk tiers are treated by percentage reduction in most current guidance. - **Statin indications beyond numbers:** diabetes mellitus above 40 years with risk factors, chronic kidney disease, prior myocardial infarction or stroke, and familial hypercholesterolaemia (LDL above 190 mg/dL in adults warrants high intensity regardless). - **Triglyceride thresholds:** above 150 mg/dL flags metabolic risk; above 500 mg/dL adds a fibrate (fenofibrate 145-200 mg daily) or omega-3 fatty acids specifically to prevent acute pancreatitis. - **Safety monitoring:** creatine kinase for muscle symptoms (myopathy, rarely rhabdomyolysis, worse with gemfibrozil or ciclosporin combinations); transaminases at baseline and if symptoms; new-onset diabetes is a small, acceptable statin risk. - **Non-statin layers:** ezetimibe 10 mg added when targets are missed; PCSK9 inhibitors for familial hypercholesterolaemia and very-high-risk patients; bempedoic acid as a newer adjunct. - **Secondary causes:** hypothyroidism, diabetes, nephrotic syndrome, chronic kidney disease, alcohol and drugs (thiazides, beta-blockers, antiretrovirals, steroids) — check thyroid-stimulating hormone before labelling it primary. - **Indian anchors:** premature coronary disease is the subcontinent's epidemic; the national NCD programme screens adults from 30 years at wellness centres, and Indian dietary patterns (refined carbohydrate, trans-fat-rich street food) raise triglycerides as often as cholesterol. ## How to work through a lipid clinic case A 48-year-old man attends after his brother's bypass surgery at 50. He smokes, his blood pressure is 146/88 mmHg on no drugs, LDL is 158 mg/dL, triglycerides 280, high-density lipoprotein 36, and HbA1c is 6.3 percent (prediabetes). Before prescribing anything permanent, exclude secondary causes: thyroid function and urine protein are normal. His risk stratification — smoking, hypertension, prediabetes, strong family history — places him in the high-risk primary-prevention tier, so atorvastatin 20-40 mg daily starts alongside an explicit lifestyle prescription, with a reassessment of lipids and liver profile at six to twelve weeks. His triglycerides of 280 do not yet justify a fibrate; they justify cutting sugar and alcohol and adding exercise, since the pancreatitis threshold is 500. Six months later, LDL is 88 on atorvastatin 40 mg; his target of under 70 is missed, so ezetimibe 10 mg is added, with his creatine kinase checked first. Compare his diabetic, post-stroke neighbour, who starts at high intensity and is pushed below 70, even towards 55 after a second event: same pharmacy shelf, different arithmetic, and the arithmetic is what the exam tests. ## How the FMGE frames it The examiner asks who gets which intensity of statin far more often than which brand-numbered molecule — expect stems built on combinations (post-MI smoker versus isolated hypertriglyceridaemia) with options graded by intensity. The fibrate question is threshold-based: 500 mg/dL is the pancreatitis trigger, and treating isolated mild hypertriglyceridaemia with fibrates instead of lifestyle is a planted error. Pharmacology one-liners cover myopathy (creatine kinase), the gemfibrozil-statin interaction, and the cytochrome logic that makes simvastatin 80 mg a retired dose. Family-screening hooks appear as familial hypercholesterolaemia — tendon xanthomata, LDL above 190, first-degree screening. The Indian layer is programme-based and increasingly tested: NCD screening under the national programme from 30 years of age, and the observation that Indian risk scores run higher at younger ages and lower BMIs than Framingham cohorts. ## Frequently asked questions ### Which patients need a high-intensity statin? Established atherosclerotic disease, LDL above 190 mg/dL, and diabetes above 40 years with additional risk factors — atorvastatin 40-80 mg or rosuvastatin 20-40 mg. ### At what triglyceride level is a fibrate added for pancreatitis prevention? Above approximately 500 mg/dL; lower levels are managed with lifestyle measures and statin-based risk reduction. ### How is statin-associated muscle disease evaluated? Creatine kinase measurement in any patient with new myalgia or weakness, withholding the drug if levels rise substantially or symptoms are severe. ### What secondary causes of dyslipidaemia must be excluded? Hypothyroidism, uncontrolled diabetes, nephrotic syndrome, chronic kidney disease, excessive alcohol and drugs such as thiazides and corticosteroids. ### From what age does India's national NCD programme screen adults for cardiovascular risk? From 30 years, under the programme framework (NPCDCS, now integrated as NP-NCD) at primary health and wellness centres.